

Bon Natural Life Limited (Nasdaq: Bon)
1H2022 Earnings Call Presentation

August 01, 2022

Confidentiality Note and Disclaimer



This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions, and our actual results may differ materially from those anticipated in these forward-looking statements.

We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Risk Factors in our registration statement filed with the SEC, including the uncertainties associated with the Company's ability to raise additional capital to finance the Company's activities; the Company's and its subsidiaries' ability to fully perform all of their obligations under the contractual obligations applicable to them; the effectiveness, profitability, and the marketability of its ongoing mix shift to more advanced products; legal and regulatory risks; the Company's ability to execute its growth strategy and the effectiveness of its increased research and developments pending; the future trading of the ordinary shares of the Company; the Company's ability to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; general economic and business conditions; the volatility of the Company's operating results and financial condition; the Company's ability to attract or retain qualified senior management personnel and research and development staff. We do not assume any obligation to update forward-looking statements as circumstances change.

Management on Call





Yongwei Hu
Chairman
Chief Executive Officer



Zhenchao LiChief Financial Officer



Yingchun XueChief Operating Officer



Wenjuan ChenChief Marketing Officer

Agenda



- CEO Perspective
- 1H 2022 Financials Overview
- Questions & Answers

CEO Perspectives



Company Overview



BON is one of the leading bio-ingredient solution providers in the natural, health and personal care industries, serving blue chip customers in both domestic China and overseas market.

Farm Sourced Raw Materials

- Apples
- · Stachys Affinis (aka, Chinese artichoke
- Clary Sage



Raw materials are processed by BON to produce the following three product categories:

- Fragrance compounds
- Health supplements (powder drinks)
- Bioactive food ingredients

Finished Products Sold By Customers

- Fragrances
- Flavorings & Sweeteners
- Powdered Drinks

Fragrance compounds and bioactive food ingredients are base active ingredients to make several different proprietary formulations by BON or its OEM & ODM customers.

Blue Chip Customers

Asia

- Tong Ren Tang
- o Kao
- Asahi
- o J2K Bio

United States

- International Flavors & Fragrances
- o Mars Wrigley
- Integrity

Europe

- Symrise
- o Fridal
- ACS International

Production Facilities & Capacities



BON currently has 2 production facilities, and the third production site – Yumen Plant is expected to commence around September 2022.

- Yumen Plant is expected to increase production capacity of fragrance compound and bioactive food ingredients by <u>200%</u>, representing an <u>150%</u> annualized growth potential in revenue.
- The first phase of Yumen Plant is to increase the production capacity of the fragrance compounds and bioactive ingredients to meet the existing market and consumer demand.
- The second phase of the expansion is for BON's new proprietary consumer products including natural prebiotics and functional personal care products.

Proprietary Product Development



FeatherPure – woman's personal care gel

- Regulate microbial balance of female productive system
- Anti-bacterial and anti-inflammatory



Cruciferous vegetable based probiotic powder drink

- Inhibit proliferation of Helicobacter pylori, a bacteria that causes digestive disease
- Regulate the microbial balance of digestive system

Other cruciferous vegetable based consumer products -

- Immune system booster in soft gel capsules;
- Digestive health booster in soft gel capsules;
- Weight loss management products;
- Sleep aid products for mid-aged and elderly.



Growth Strategies



Within a Year



Operation Expansion

Global operation expansion: currently looking for opportunities to develop sales and marketing channels in U.S., EU, and Asia.



Production Capacity

Yumen Plant is expected to increase production capacity by 200%.



Product Development

Product line expansion in both raw materials and proprietary consumer products.



Strategic Partnership & Synergetic Acquisition

Plan to pursue 2-3 merger and acquisition to expand new business and achieve growth.

1H 2022 Financials Overview



Summary Financials




Strong growth driven by changes in number of customers, sales volume, selling price and mix of products.

- During the six months ended March 31, 2022, sales increased to \$13.7M, an <u>increase of 17.0%</u> over the same period in previous year.
 - Increased in average selling price of fragrance compounds (64.1%), powder drinks (11.2%) and bioactive food ingredients (79.2%).
- Both gross profit and net income also increased by 19.6% and 10.2%, respectively.

Income Statement	For the Six-Month ended March 31			
	1H 2021	1H 2022	Change	
Total Revenue	\$11.7M	\$13.7M	17.0%	
Gross Profit	\$3.4M	\$4.0M	19.6%	
Gross Profit Margin	28.8%	29.5%	0.7%	
Net Income	\$2.3M	\$2.5M	10.2%	

Segment Growth






There was significant growth in two segments:

- Fragrance compounds (+24.9%)
- Bioactive food ingredients (+171.8%)


Decrease from health supplement (powder drinks) was mainly due to the decrease in sales volume, which was caused by the raw material shortage in the second half of 2021 and the logistics disruption caused by COVID-19.



Geographic Growth



Revenues in the Six-month Ended March 31, 2022 (by Geography) (Unaudited)



Geographical Sales Growth (For the Six-month Ended March 31) (Unaudited)						
	1H 2021	% of Total	1H 2022	% of Total		
China	\$10.7	91.8%	\$13.1	95.7%		
Overseas (Ex-PRC)	\$1.0	8.2%	\$0.6	4.3%		
Total	\$11.7	\$13.7				
	-	The % of domestic China sales vs. international sales increased due to new sales strategy in response to global supply chain disruption				

 We shifted our sales strategy by directing more marketing efforts to promote our products to large domestic enterprise clients due to disruptions of logistics caused by COVID-19 resurgence.

Subsequent Events



Third production site – Yumen Plant has completed the building structure of the facility as scheduled and forecasted to commence around September 2022.

June 2022 • Lau

May 2022

Launched a new cruciferous vegetable based probiotic powder drink.

Appointment of Jeffrey Guzy, as a new independent director to its Board of Directors and as Chair of the Audit Committee.



Q&A



- To ask a question you may <u>press * then 1</u> on your touch-tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question please <u>press * then 2</u>.
- For those on the webcast, You may submit questions by typing in the Submit a Question box on your screen.



Bon Natural Life Limited (Nasdaq: Bon) 1H2022 Earnings Call Presentation

August 01, 2022

Principal Executive Offices: C601, Gazelle Valley, No.69 Jinye Road. Xi'an Hi-tech Zone, Xi'an, China